Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.63 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.55 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.55 |
| ▸ | IARS1 | P41252 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14424395 | 0.88 | ADORA1 (0.79) | ADORA3ADORA1ADORA2A | |
| SCHEMBL19837855 | 0.88 | ADORA3 (0.79) | ADORA3ADORA1ADORA2APRMT5WDR77 | |
| SCHEMBL5354088 | 0.85 | ADORA3 (1.00) | ADORA3ADORA2A | |
| SCHEMBL5354093 | 0.85 | ADORA3 (1.00) | ADORA3ADORA2A | |
| SCHEMBL19837838 | 0.85 | ADORA3 (0.80) | ADORA3ADORA1ADORA2APRMT5WDR77 | |
| SCHEMBL19837864 | 0.84 | ADORA3 (0.74) | ADORA3ADORA1ADORA2APRMT5WDR77 | |
| SCHEMBL19837865 | 0.82 | ADORA3 (0.69) | ADORA3ADORA1ADORA2AIARS1 | |
| SCHEMBL3692106 | 0.78 | ADORA3 (0.74) | ADORA3ADORA1ADORA2A | |
| SCHEMBL1961097 | 0.78 | ADORA3 (0.74) | ADORA3ADORA1ADORA2A | |
| SCHEMBL4384509 | 0.77 | ADORA3 (1.00) | ADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | UTI LIMITED PARTNERSHIP (CA) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | PNP, NUDT1, SLC29A1 | ADORA3 78/4885ADORA1 73/4885ADORA2A 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.